IMRA IMARA Inc.

Biotech Analyst Ratings

Latest News

1. 05 April 2022 Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

   Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat population
   

   Interim results in Forte trial for beta-thalassemia demonstrated no meaningful benefit in transfusion burden or improvement in most disease-related biomarkers

   Tovinontrine was generally well-tolerated across studies

   Both Phase 2b clinical trials and further development of tovinontrine in sickle cell and beta-thalassemia to be discontinued

   BOSTON, April 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA) today announced results from interim analyses of its Ardent Phase 2b clinical trial of tovinontrine (IMR-687) in patients with…

   View Full Article
2. 15 March 2022 Imara Reports Full Year 2021 Financial Results and Business Highlights

   Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022
   

   Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease to reductions in annualized rate of VOCs at written request of the FDA

   Added clinical indication for tovinontrine to include the treatment of HFpEF;
   anticipate first subject dosing in Phase 2 trial in second quarter of 2022

   Expanded pipeline with addition of IMR-261, an oral, clinic-ready Nrf2 activator
   with potential indications in hemoglobin and iron overload disorders

   Company to host conference call and live webcast today at 8:30 AM ET

   BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Imara Inc…

   View Full Article
3. 08 March 2022 Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

   BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 15, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2021 and review recent business highlights.
   

   A live webcast will be available under "Events and Presentations" in the Investors section of the company's website. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800-3873 (international) and referring to conference ID…

   View Full Article
4. 10 February 2022 Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

   BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m. ET. 

   A replay of the webcast will be archived on the "Events and Presentations" section of Imara's website. 
   
   About Imara
   Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat…

   View Full Article
5. 25 January 2022 Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

   Expanding patient base and potential of Imara's small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders
   

   Phase 2 trial aims to select HFpEF patients with enriched PDE9 expression
   for targeted approach to a heterogeneous disease

   Study initiation planned for second quarter of 2022

   BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) --  Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for tovinontrine (IMR-687) to commence clinical development…

   View Full Article